Goodwin Procter advised Grey Wolf Therapeutics on the deal, while DLA Piper advised Pfizer Ventures and Earlybird Venture Capital.Grey Wolf Therapeutics announced its $49 million Series B funding…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
